Aug 2012

Home >> Clinical Trials News Archive >> 2012 >> Aug 2012
Deloitte: Israel ranked 4th in confidence for VC investments. The 2012 Global Venture Capital Confidence Survey by Deloitte and the US National Venture Capital Association ranked Israel fourth in overall confidence in investing, after the US, Brazil, and China.
 
Nobel-prize winner Prof. Ada Yonath will head a delegation of about 100 Israeli participants to the Life Sciences Baltics 2012 (www.lsb2012.com) conference in Vilnius, Lithuania Sept.12-14. The conference will showcase the rapidly growing life science industries of Lithuania, Estonia and Latvia and will include partnering events and company visits.
 
Israeli Women Ahead in Science Poised to Lead in Biotech. Women outnumber men in biology and related sciences in higher education in Israel. That could give women an advantage as the government and private investors put increasing amounts of money into the life-sciences industry, one of the country’s fastest growing sectors, collecting the most venture capital money in the first half of this year. 
 
Globalization White Paper by The Association of Clinical Research Organizations (ACRO) was published. This report analyzes the current state of global clinical research and the role that biopharmaceutical companies and their clinical research organization (CRO) partners play in ensuring that the dual goals of trial safety and quality are met.
 
New ACRO Video Series Debuts. The Association of Clinical Research Organizations (ACRO) today announced the release of a new video series on itsYouTube Channel. The videos were selected from an executive roundtable session held during this year’s Annual Meeting of the Drug Information Association. The following videos and subsequent topics will be released throughout the month of August viaACRO’s Twitter Account
 
No Regional Differences in Quality of Clinical Trial Data. “A formal statistical evaluation indicates no significant differences in data quality for clinical trials conducted in developing regions relative to mature regions,” says an article published in the July 2012 issue of the Drug Information Journal.  The article by Pankaj B. Desai, PhD, of the Drug Development Graduate Program, College of Pharmacy at the University of Cincinnati, analyzed 26 large-scale multi-regional Phase II/III clinical trials enrolling nearly 64,000 participants at more than 4,700 research sites.